Platforms often have infinite possibilities. How do you choose the best possible indication or products?
Immune Biosolutions retained the Novateur Clinical and Business Development team to conduct an assessment of Immune Biosolutions’ therapeutic pipeline and layout the key steps necessary to advance two of their therapeutics pipeline’s projects up to CTA/IND. The assessment of the pipeline to include a general competitive landscape in terms of target/indication chosen and strengths and challenges of therapeutic in its proposed indication.
In 2017, within 4 weeks the Novateur team completed such assessment which included:
Recommendation on targets, including Outlining steps and advice in target validation and lead selection
Recommendations on indications/diseases
Recommendations on development paths
Competitive analysis of the space for each indication
Gantt charts, development plans, timelines, and topline budgets
In 2018, Immune Biosolutions received a term sheet from a major pharmaceutical partner. The Immune Biosolutions team retained the Novateur business development team to assist in negotiating the agreements and contracts between the two companies. We were delighted to assist Immune Biosolutions in successfully completing their first collaboration deal with a major global pharmaceutical company.
Our support for Immune Biosolutions on subsequent business development activities continues to this day.